Efficacy and safety of antiplatelet drugs in patients with chronic kidney disease
İbrahim Yıldız, Pınar Özmen Yıldız, Oben Döven
Türk Kardiyoloji Derneği Arşivi · 2014
doi:10.5543/tkda.2014.08838 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
The risks and benefits of antiplatelet treatment may be different in patients with chronic kidney disease, in whom tendency to thrombosis and bleeding hazards might be increased. Chronic kidney disease is also associated with poor response to antiplatelet therapy, and this represents a potentially important clinical problem in the setting of percutaneous coronary intervention and acute coronary syndrome. The use of new, potent P2Y12 inhibitors appears promising, although special consideration should be given to possible bleeding events. This review evaluates the benefits and harms of antiplatelet drugs in patients with chronic kidney disease.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.